ClinicalTrials.gg
WithdrawnNCT06329414Updated Nov 6, 2026

Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis

An observational study in Multiple Sclerosis, Major Depressive Disorder and Treatment Resistant Depression, sponsored by University of Utah. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Utah · Observational

How we know

Why this study was withdrawn
Recruitment Failure
Updated Nov 6, 2026Now WithdrawnPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 258 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
290th of 302
0 · median 100
Started
2024
with 56 others
Observational
302 of 1,192
51 open now
Registered
1,048th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 290th largest by enrollment of the 302 observational ones that give a count, is one of 57 that started in 2024, is one of 302 observational ones, and was the 1,048th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS. Participants will receive outpatient TMS treatment over the course of 5-6 weeks. Participants will complete validated questionnaires and exams before, during, and after treatment.

Read the detailed description

Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system. Depression, or major depressive disorder, is highly prevalent in people with MS and often has a serious impact on quality of life. MDD can be difficult to treat with medications in MS. Transcranial magnetic stimulation (TMS) is a safe and approved treatment for treatment-resistant depression in the general population. However, little is known about the use of TMS for MDD in people with MS. This pilot study will evaluate the safety, feasibility, and preliminary efficacy of TMS for MDD in MS. Participants will receive outpatient neuronavigated-TMS for MDD. Various measures of MS and MDD symptoms will be monitored over the course of treatment. Clinical brain imaging will also be compared before and after TMS.

03

Conditions studied

  • Multiple Sclerosis
  • Major Depressive Disorder
  • Treatment Resistant Depression

Keywords

  • multiple sclerosis
  • depression
  • major depressive disorder
  • treatment resistant depression
  • transcranial magnetic stimulation
  • TMS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults diagnosed with MDD and MS who are eligible for TMS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established diagnosis of multiple sclerosis (any subtype) by 2017 McDonald criteria
  • Established diagnosis of major depressive disorder (MDD) by criteria
  • Eligible for transcranial magnetic stimulation (rTMS) for depression

Exclusion criteria

Exclusion Criteria:

  • MS relapse and/or use within 3 months
  • Active suicidal ideation
  • History of seizure/epilepsy, brain tumor, or stroke
  • History of bipolar disorder or psychosis
  • Currently or planning to become pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Feasibility of TMS treatment for MDD, per participant retention rates.

    Time frame: 10 weeks

  2. Safety and tolerability, to be evaluated by side effects and adverse events over the course of treatment.

    Time frame: 10 weeks

Secondary outcomes

  1. Depression response rates (50% reduction in symptoms) will be measured using MADRS scores before and after treatment.

    Time frame: 10 weeks

  2. Depression remission rates will be measured using MADRS scores before and after treatment.

    Time frame: 10 weeks

  3. MS lesion burden on MRI will be compared before and after treatment to determine impact of TMS on white matter disease burden.

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2024 to primary completion in Jan 2025, 11 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jan 2026 → Jan 2025 and completion Jan 2026 → Jan 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Mar 25, 2024
StartActual
Jan 16, 2024
Primary completionActual
Jan 10, 2025was Jan 2026
CompletionActual
Jan 10, 2025was Jan 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn Recruitment Failure
changed Nov 6, 2026
Primary completion
Jan 2026→Jan 10, 2025 (actual)
Nov 6, 2026
Study completion
Jan 2026→Jan 10, 2025 (actual)
Nov 6, 2026
Enrollment
12 (estimated)→0 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Withdrawn
    Why stopped Recruitment Failure
    Primary completion Jan 2026→Jan 10, 2025 (now actual)
    Study completion Jan 2026→Jan 10, 2025 (now actual)
    Enrollment 12 (estimated)→0 (actual)
    + 4 other changes: responsible party, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06329414
Lead sponsor
University of Utah
Responsible party
Sponsor
First posted
Mar 25, 2024
Start date
Jan 16, 2024
Primary completion
Jan 10, 2025
Completion
Jan 10, 2025
Last update
Nov 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion